Ovarian cancer patients with germline BRCA1/2 mutations are sensitive to platinum-based therapies and demonstrate improved survival [77]; however, if they develop a secondary somatic BRCA1/2 mutation, platinum-resistance ensues [78]. Here, BRCA1 is linked to ovarian carcinoma.